Cotellic

(cobimetinib)
Cotellic 20 MG Oral Tablet
NO BOXED WARNING

Dosage & administration

drug label

Cotellic prescribing information

prior authorization

Cotellic prior authorization resources

Most recent Cotellic prior authorization forms

View By Payer
Verified: Feb 07, 2024Kaiser Foundation Health Plan - Chronic High-Dose Opioid Therapy Prior Authorization Form Washington
Verified: Mar 02, 2024Highmark BCBS Northeastern NY - Medicare Prescription Drug Medication Request Form
Verified: Mar 02, 2024Highmark BCBS Northeastern NY - Short Acting Opioid Prior Authorization Form
Verified: Mar 02, 2024Highmark BCBS Western NY - Specialty Drug Prior Authorization Form
Verified: Mar 02, 2024Highmark BCBS Western NY - Non-Formulary Drug Coverage Prior Authorization Form

Most recent state uniform prior authorization forms

Verified: Feb 27, 2024Arizona - Uniform Prior Authorization Form
Verified: Feb 27, 2024Colorado - Uniform Prior Authorization Form
Verified: Feb 27, 2024Hawaii - Uniform Prior Authorization Form
Verified: Feb 27, 2024Illinois - Uniform Prior Authorization Form
Verified: Feb 27, 2024Indiana - Uniform Prior Authorization Form
Verified: Feb 27, 2024Louisiana - Uniform Prior Authorization Form
Verified: Feb 27, 2024Michigan - Uniform Prior Authorization Form
Verified: Feb 27, 2024Minnesota - Uniform Prior Authorization Form
Verified: Feb 27, 2024New Hampshire - Uniform Prior Authorization Form
Verified: Feb 27, 2024New Mexico - Uniform Prior Authorization Form
Verified: Feb 27, 2024Oregon - Uniform Prior Authorization Form
Verified: Feb 27, 2024Texas - Uniform Prior Authorization Form
Complete Letter of Medical Necessity
Coverage Authorization Appeals
Learn More

Benefits investigation

Cotellic Prescriber Service Form - Online Portal
Learn More

Reimbursement help (FRM)

Receive Assistance from an FRM Regarding Reimbursement Information
Learn More

pharmacy

Cotellic preferred pharmacy

Pharmacy List

financial assistance

Cotellic financial assistance options

Co-pay savings program

commercial only
Cotellic Prescriber Service Form - Online Portal
Enroll in Patient Savings Program
Learn More

Foundation programs

under insured
no insurance
goverment insurance
65+
Cotellic Prescriber Service Form - Online Portal
Genentech Patient Foundation Application Form (1/2)
Learn More

PubMed™ | Cotellic

Cotellic PubMed™ News

patient education

Cotellic patient education

To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link

Patient toolkit

View How to Take Cotellic
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Side Effects
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Resources
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Learn More

people also ask

Cotellic FAQs

Is Zelboraf safe to use during pregnancy?Zelboraf can potentially cause harm to a fetus when used by pregnant women. Limited data is available, but placental transfer to the fetus has been reported. Pregnant women should be informed of the potential risks to the fetus.
Are there risks associated with breastfeeding while using Zelboraf?No information exists regarding the presence of Zelboraf in human milk or its effects on infants or milk production. Due to potential adverse reactions in infants, including serious conditions like malignancy and dermatologic reactions, women are advised not to breastfeed during Zelboraf treatment and for 2 weeks after the final dose.
What precautions should females and males of reproductive potential take while using Zelboraf?Females of reproductive potential should use effective contraception during Zelboraf treatment and for 2 weeks after the last dose due to the potential risk of fetal harm. Males should also take precautions, and those with female partners of reproductive potential should use condoms during treatment and for 2 weeks after the last dose.
Is Zelboraf approved for use in pediatric patients?The safety and effectiveness of Zelboraf in pediatric patients have not been fully established, although limited studies were conducted in adolescents with specific melanoma types. Further research is needed to determine its safety profile in this population.
What information is available regarding Zelboraf use in older adults?Clinical studies for Zelboraf did not include enough elderly subjects to determine if they respond differently from younger individuals.
Are there recommended dosage adjustments for patients with liver or kidney impairment?For patients with mild or moderate liver or kidney impairment, no dosage adjustment is recommended based on available analyses. However, the appropriate dose has not been established for patients with severe impairment in these organs.
FAQ Data Source